Compare State Street PDR S&P Retail ETF (XRT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street PDR S&P Retail ETF vs Zoetis Inc — how do they compare? State Street PDR S&P Retail ETF trades at $84.3, while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Zoetis Inc pays a 2.89% dividend while State Street PDR S&P Retail ETF pays none, and State Street PDR S&P Retail ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| XRT | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $92.35 | $150.61 |
52-Week Low | $77.28 | $71.91 |
Market Cap | — | $30.29B |
Enterprise Value | — | $37.86B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XRT (SPDR S&P Retail ETF) trades at $85.70, down 2.16% amid bearish technical signals, with moving averages indicating a downtrend and RSI levels in neutral territory. Recent news highlights unusual options activity with a 145% surge in put volume (Defense World, 2026-09-09) and mixed retail sector data, including a 0.6% drop in July sales (ETF Trends, 2026-08-14). The ETF offers exposure to consumer discretionary retail, with a dividend scheduled for June 2026.
Outlook is cautious due to technical weakness and sector headwinds like inflation and shifting consumer spending. Risks include economic sensitivity and competitive pressures, but potential exists if retail resilience improves. Investors should weigh bearish signals against long-term value opportunities in selective retail segments.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
